The authors declare that they have no competing interests.
GWH performed statistical analysis and oversaw drafting of the manuscript. LK and LV performed literature reviews and assisted in the drafting of the manuscript. KH, BNP and EP provide project management and oversight in participant recruitment and data management. EP conducted interviews and coordinated survey collection. KG, BNP, CI, KT participated in the design of the study and clinical recruitment of the original cohorts of participants. MDS conceived of the study, participated in design and coordination, oversaw the statistical analysis and helped to draft the manuscript. All authors read and approved the final manuscript.
As BRCA1/2 testing becomes more routine, questions remain about long-term satisfaction and quality of life following testing. Previously, we described long term distress and risk management outcomes among women with BRCA1/2 mutations. This study addresses positive psychological outcomes in BRCA1/2 carriers, describing decision satisfaction and quality of life in the years following testing.
We evaluated satisfaction with testing and management decisions among 144 BRCA1/2 carriers. Prior to genetic testing, we assessed family history, sociodemographics and distress. At a mean of 5.3 years post-testing, we assessed management decisions, satisfaction with decisions and, among women with cancer, quality of life.
Overall, satisfaction with decision making was high. Women who had risk reducing mastectomy or oophorectomy were more satisfied with management decisions. Participants who obtained a risk reducing oophorectomy were more satisfied with their genetic testing decision. Among affected carriers, high pretest anxiety was associated with poorer quality of life and having had risk reducing mastectomy prior to testing was associated with better quality of life. The negative impact of pre-test anxiety was diminished among women who had mastectomies before testing.
BRCA1/2 carriers are satisfied with their testing and risk management decisions and report good quality of life years after testing. Having risk reducing surgery predicts increased satisfaction and improved quality of life.
Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, Khan SA, Krontiras H, Lyman G, Rafferty E, Shaw S, Smith ML, Tsangaris TL, Williams C, Yaneeklov T: NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw 2009, 7(10):1060–1096. PubMed
Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, Morris E, Pisano E, Schnall M, Sener S, Smith RA, Warner E, Yaffe M, Andrews KS, Russell CA, and the American Cancer Society Breast Cancer Advisory Group: American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007, 57(2):75–89. 10.3322/canjclin.57.2.75 CrossRefPubMed
Schwartz MD, Lerman C, Brogan B, Peshkin BN, Halbert CH, DeMarco T, Lawrence W, Main D, Finch C, Magnant C, Pennanen M, Tsangaris T, Wiley S, Isaacs C: Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 2004, 22(10):1823–1829. 10.1200/JCO.2004.04.086 CrossRefPubMed
Metcalfe KA, Birenbaum-Carmeli D, Lubinski J, Gronwald J, Lynch H, Moller P, Ghadirian P, Foulkes WD, Klijn J, Friedman E, Kim-Sing C, Ainsworth P, Rosen B, Domchek S, Wagner T, Tung N, Manouklan S, Couch F, Sun P, Narod S: International variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers. Int J Cancer 2008, 122(9):2017–2022. 10.1002/ijc.23340 CrossRefPubMedPubMedCentral
Metcalfe KA, Lubinski J, Ghadirian P, Lynch H, Kim-Sing C, Friedman E, Foulkes WD, Domchek S, Ainsworth P, Isaacs C, Tung N, Gronwald J, Cummings S, Wagner T, Manouklan S, Moller P, Sun P, Narod S, Tung N, Gronwald J, Cummings S, Wagner T, Manouklan S, Moller P, Sun P, Narod S: Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 2008, 26(7):1093–1097. 10.1200/JCO.2007.12.6078 CrossRefPubMed
Evans DG, Lalloo F, Ashcroft L, Shenton A, Clancy T, Baildam AD, Brain A, Hopwood P, Howell A: Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomarkers Prev 2009, 18(8):2318–2324. 10.1158/1055-9965.EPI-09-0171 CrossRefPubMed
Geiger AM, West CN, Nekhlyudov L, Herrinton LJ, Liu IL, Altschuler A, Rolnick SJ, Harris EL, Greene SM, Elmore JG, Emmons KM, Fletcher SW: Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol 2006, 24(9):1350–1356. 10.1200/JCO.2005.01.9901 CrossRefPubMed
Frost MH, Schaid DJ, Sellers TA, Slezak JM, Arnold PG, Woods JE, Petty PM, Johnson JL, Sitta DL, McDonnell SK, Rummans TA, Jenkins RB, Sloan JA, Hartmann LC: Long-term satisfaction and psychological and social function following bilateral prophylactic mastectomy. JAMA 2000, 284(3):319–324. 10.1001/jama.284.3.319 CrossRefPubMed
Westin SN, Sun CC, Lu KH, Schmeler KM, Soliman PT, Lacour RA, Johnson KG, Daniels MS, Arun BK, Peterson SK, Bodurka DC: Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer 2011, 117(12):2659–2667. 10.1002/cncr.25820 CrossRefPubMed
Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, Gaarenstroom KN, Mourits MJ, Verheijen RH, van Dorst EB, Putten H, Velden K, Boonstra H, Aaronson NK: Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 2005, 23(28):6890–6898. 10.1200/JCO.2005.02.626 CrossRefPubMed
Brandberg Y, Sandelin K, Erikson S, Jurell G, Liljegren A, Lindblom A, Linden A, von Wachenfeldt A, Wickman M, Arver B: Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol 2008, 26(24):3943–3949. 10.1200/JCO.2007.13.9568 CrossRefPubMed
Tercyak KP, Peshkin BN, Brogan BM, DeMarco T, Pennanen MF, Willey SC, Magnant CM, Rogers S, Isaacs C, Schwartz MD: Quality of life after contralateral prophylactic mastectomy in newly diagnosed high-risk breast cancer patients who underwent BRCA1/2 gene testing. J Clin Oncol 2007, 25(3):285–291. 10.1200/JCO.2006.07.3890 CrossRefPubMed
Isern AE, Tengrup I, Loman N, Olsson H, Ringberg A: Aesthetic outcome, patient satisfaction, and health-related quality of life in women at high risk undergoing prophylactic mastectomy and immediate breast reconstruction. J Plast Reconstr Aesthet Surg 2008, 61(10):1177–1187. 10.1016/j.bjps.2007.08.006 CrossRefPubMed
Graves KD, Vegella P, Poggi EA, Peshkin BN, Tong A, Isaacs C, Finch C, Kelly S, Taylor KL, Luta G, Schwartz MD: Long-term psychosocial outcomes of BRCA1/BRCA2 testing: differences across affected status and risk-reducing surgery choice. Cancer Epidemiol Biomarkers Prev 2012, 21(3):445–455. 10.1158/1055-9965.EPI-11-0991 CrossRefPubMedPubMedCentral
Graves KD, Wenzel L, Schwartz MD, Luta G, Wileyto P, Narod S, Peshkin BN, Marcus A, Cella D, Emsbo SP, Barnes D, Hughes Halbert C: Randomized controlled trial of a psychosocial telephone counseling intervention in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2010, 19(3):648–654. 10.1158/1055-9965.EPI-09-0548 CrossRefPubMedPubMedCentral
Schwartz MD, Valdimarsdottir HB, DeMarco TA, Peshkin BN, Lawrence W, Rispoli J, Brown K, Isaacs C, O'Neill S, Shelby R, Grumet SC, McGovern MM, Garnett S, Bremer H, Leeman S, O’Mara K, Kelleher S, Komaridis K: Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction. Health Psychol 2009, 28(1):11–19. CrossRefPubMedPubMedCentral
Spielberger CD, Gorsuch RL, Lushene PR, Vagg PR, Jacobs GA: Manual for the State-Trait Anxiety Inventory. Palo Alto, CA: Consulting Psychologists Press, Inc.; 1983.
Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G: Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 1997, 15(3):974–986. PubMed
Frost MH, Hoskin TL, Hartmann LC, Degnim AC, Johnson JL, Boughey JC: Contralateral prophylactic mastectomy: long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits. Ann Surg Oncol 2011, 18(11):3110–3116. 10.1245/s10434-011-1917-7 CrossRefPubMedPubMedCentral
- Long-term satisfaction and quality of life following risk reducing surgery in BRCA1/2 mutation carriers
Gillian W Hooker
Beth N Peshkin
Kathryn L Taylor
Marc D Schwartz
- BioMed Central
Neu im Fachgebiet Onkologie
Mail Icon II